Squitieri F - Search Results

1

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, Frati L, Mansi L, Ciarmiello A. Squitieri F, et al. Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1113-20. doi: 10.1007/s00259-009-1103-3. Epub 2009 Mar 11. Eur J Nucl Med Mol Imaging. 2009. PMID: 19280185 Clinical Trial.

2

Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis.

Squitieri F, Berardelli A, Nargi E, Castellotti B, Mariotti C, Cannella M, Lavitrano ML, de Grazia U, Gellera C, Ruggieri S. Squitieri F, et al. Clin Genet. 2000 Jul;58(1):50-6. doi: 10.1034/j.1399-0004.2000.580108.x. Clin Genet. 2000. PMID: 10945661

3

Cavernous angiomas of the nervous system in Italy: clinical and genetic study.

Squitieri F, Maglione V, Buzzi MG, Nargi E, Novelletto A, Cannella M, Simonelli M, Colonnese C, Simonelli P, Innocenzi G, Gagliardi FM, Caruso R, Ragona G, Cantore GP. Squitieri F, et al. Neurol Sci. 2000 Jun;21(3):129-34. doi: 10.1007/s100720070087. Neurol Sci. 2000. PMID: 11076000

4

Short-term effects of olanzapine in Huntington disease.

Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Squitieri F, et al. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):69-72. Neuropsychiatry Neuropsychol Behav Neurol. 2001. PMID: 11234911

5

Presymptomatic tests in Huntington's disease and dominant ataxias.

Cannella M, Simonelli M, D'Alessio C, Pierelli F, Ruggieri S, Squitieri F. Cannella M, et al. Among authors: squitieri f. Neurol Sci. 2001 Feb;22(1):55-6. doi: 10.1007/s100720170044. Neurol Sci. 2001. PMID: 11487199

6

Onset and pre-onset studies to define the Huntington's disease natural history.

Squitieri F, Cannella M, Giallonardo P, Maglione V, Mariotti C, Hayden MR. Squitieri F, et al. Brain Res Bull. 2001 Oct-Nov 1;56(3-4):233-8. doi: 10.1016/s0361-9230(01)00648-7. Brain Res Bull. 2001. PMID: 11719256 Review.

7

CAG mutation effect on rate of progression in Huntington's disease.

Squitieri F, Cannella M, Simonelli M. Squitieri F, et al. Neurol Sci. 2002 Sep;23 Suppl 2:S107-8. doi: 10.1007/s100720200092. Neurol Sci. 2002. PMID: 12548366

8

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.

Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD. Squitieri F, et al. Brain. 2003 Apr;126(Pt 4):946-55. doi: 10.1093/brain/awg077. Brain. 2003. PMID: 12615650

9

Highly disabling cerebellar presentation in Huntington disease.

Squitieri F, Pustorino G, Cannella M, Toscano A, Maglione V, Morgante L, Tortorella G. Squitieri F, et al. Eur J Neurol. 2003 Jul;10(4):443-4. doi: 10.1046/j.1468-1331.2003.00601.x. Eur J Neurol. 2003. PMID: 12823498 No abstract available.

10

Aberrant A2A receptor function in peripheral blood cells in Huntington's disease.

Varani K, Abbracchio MP, Cannella M, Cislaghi G, Giallonardo P, Mariotti C, Cattabriga E, Cattabeni F, Borea PA, Squitieri F, Cattaneo E. Varani K, et al. Among authors: squitieri f. FASEB J. 2003 Nov;17(14):2148-50. doi: 10.1096/fj.03-0079fje. Epub 2003 Sep 4. FASEB J. 2003. PMID: 12958155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters